



**Helmut R Maecke**

**Kontakt**

Helmut R Maecke

## Publikationen (9)

Forrer F, Oechslin-Oberholzer C, Campana B, Herrmann R, Maecke H, Mueller-Brand J, Lohri A. Radioimmunotherapy with <sup>177</sup>Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. *J Nucl Med* 2013; 54:1045-52.

Ambrosini V, Fani M, Fanti S, Forrer F, Maecke H. Radiopeptide imaging and therapy in Europe. *J Nucl Med* 2011; 52 Suppl 2:42S-55S.

Abiraj K, Mansi R, Tamma M, Fani M, Forrer F, Nicolas G, Cescato R, Reubi J, Maecke H. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. *J Nucl Med* 2011; 52:1970-8.

Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi J, Maecke H. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. *Eur J Nucl Med Mol Imaging* 2010; 38:97-107.

Abiraj K, Mansi R, Tamma M, Forrer F, Cescato R, Reubi J, Akyel K, Maecke H. Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours. *Chemistry* 2010; 16:2115-24.

Mansi R, Wang X, Forrer F, Kneifel S, Tamma M, Waser B, Cescato R, Reubi J, Maecke H. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. *Clin Cancer Res* 2009; 15:5240-9.

Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, Moldenhauer G, Maecke H. In vitro characterization of (<sup>177</sup>Lu)-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. *Eur J Nucl Med Mol Imaging* 2009; 36:1443-52.

Forrer F, Waldherr C, Maecke H, Mueller-Brand J. Targeted radionuclide therapy with <sup>90</sup>Y-DOTATOC in patients with neuroendocrine tumors. *Anticancer Res* 2006; 26:703-7.

Forrer F, Uusijärvi H, Storch D, Maecke H, Mueller-Brand J. Treatment with <sup>177</sup>Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with <sup>90</sup>Y-DOTATOC. *J Nucl Med* 2005; 46:1310-6.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)